Costs of orphan medicinal products: longitudinal analysis of expenditure in Wales.
Costs analysis, health economics
Drug costs
Orphan Drugs
Journal
Orphanet journal of rare diseases
ISSN: 1750-1172
Titre abrégé: Orphanet J Rare Dis
Pays: England
ID NLM: 101266602
Informations de publication
Date de publication:
01 Nov 2023
01 Nov 2023
Historique:
received:
24
09
2021
accepted:
19
10
2023
medline:
3
11
2023
pubmed:
2
11
2023
entrez:
2
11
2023
Statut:
epublish
Résumé
The Orphan Regulation ((EC) No 141/2000) has successfully redirected private and public investment towards previously neglected areas through incentives, regulatory obligations and rewards. However, the growth in the number of licensed orphan medicinal products (OMPs) has led to concerns about increased costs. The aims were to investigate the trend in the costs of OMPs to the National Health Service in Wales, to attribute costs of medicines within and outside periods of marketing exclusivity, and estimate the contribution of individual medicines to the overall costs of OMPs. Expenditure on OMPs in Wales was analysed between the 2014/15 and 2019/20 financial years using data on prescriptions dispensed in primary care, secondary care, and specialised commissioned services. OMP spend was calculated as a proportion of total medicines expenditure, whether it was incurred during, or outside the marketing exclusivity period (MEP), and by therapeutic area and medicine. Overall spend on OMPs and all medicines increased from £32 m to £82 m, and from £1,030 m to £1,198 m, respectively, with the proportion of spend on OMPs more than doubling from 3.1% to 6.9% per annum. Average year-on-year growth in the costs of OMPs was 21%, compared to 2% for other medicines. Costs following MEP expiry contributed significantly to overall OMP costs, increasing from £8 m to £30 m, corresponding to an increase from 24% to 37%. Treatments for 'malignant disease and immunosuppression', 'nutrition and blood' and the 'respiratory system' accounted for 90% of all OMP spend. Half of total OMP annual expenditure was on just 4 medicines in 2014/15, increasing to 8 in 2019/20. Both the number of OMPs and the amount spent on OMPs in Wales has increased over time, possibly as a consequence of favourable licensing conditions, permissive health technology assessment policies and dedicated funding.
Sections du résumé
BACKGROUND
BACKGROUND
The Orphan Regulation ((EC) No 141/2000) has successfully redirected private and public investment towards previously neglected areas through incentives, regulatory obligations and rewards. However, the growth in the number of licensed orphan medicinal products (OMPs) has led to concerns about increased costs. The aims were to investigate the trend in the costs of OMPs to the National Health Service in Wales, to attribute costs of medicines within and outside periods of marketing exclusivity, and estimate the contribution of individual medicines to the overall costs of OMPs.
METHODS
METHODS
Expenditure on OMPs in Wales was analysed between the 2014/15 and 2019/20 financial years using data on prescriptions dispensed in primary care, secondary care, and specialised commissioned services. OMP spend was calculated as a proportion of total medicines expenditure, whether it was incurred during, or outside the marketing exclusivity period (MEP), and by therapeutic area and medicine.
RESULTS
RESULTS
Overall spend on OMPs and all medicines increased from £32 m to £82 m, and from £1,030 m to £1,198 m, respectively, with the proportion of spend on OMPs more than doubling from 3.1% to 6.9% per annum. Average year-on-year growth in the costs of OMPs was 21%, compared to 2% for other medicines. Costs following MEP expiry contributed significantly to overall OMP costs, increasing from £8 m to £30 m, corresponding to an increase from 24% to 37%. Treatments for 'malignant disease and immunosuppression', 'nutrition and blood' and the 'respiratory system' accounted for 90% of all OMP spend. Half of total OMP annual expenditure was on just 4 medicines in 2014/15, increasing to 8 in 2019/20.
CONCLUSIONS
CONCLUSIONS
Both the number of OMPs and the amount spent on OMPs in Wales has increased over time, possibly as a consequence of favourable licensing conditions, permissive health technology assessment policies and dedicated funding.
Identifiants
pubmed: 37915031
doi: 10.1186/s13023-023-02956-3
pii: 10.1186/s13023-023-02956-3
pmc: PMC10621215
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
342Subventions
Organisme : HCRW_
ID : Health and Care Research Wales
Pays : United Kingdom
Informations de copyright
© 2023. The Author(s).
Références
Orphanet J Rare Dis. 2021 Jun 30;16(1):292
pubmed: 34193232
Pharmacoeconomics. 2018 May;36(5):613-624
pubmed: 29520603
Value Health. 2012 Dec;15(8):1182-4
pubmed: 23244822
Orphanet J Rare Dis. 2019 May 3;14(1):95
pubmed: 31053154
Orphanet J Rare Dis. 2019 Dec 11;14(1):287
pubmed: 31829218
Value Health. 2018 May;21(5):538-546
pubmed: 29753350
Br J Clin Pharmacol. 2021 Jun;87(6):2444-2449
pubmed: 32495405
Front Pharmacol. 2019 Nov 27;10:1279
pubmed: 31827433
Value Health. 2018 May;21(5):553-560
pubmed: 29753352
Orphanet J Rare Dis. 2018 Nov 15;13(1):206
pubmed: 30442155
BMJ. 2020 Jul 28;370:m2983
pubmed: 32727745
Orphanet J Rare Dis. 2012 Sep 26;7:74
pubmed: 23013790
Folia Med (Plovdiv). 2018 Mar 1;60(1):79-91
pubmed: 29668449
Orphanet J Rare Dis. 2014 Feb 13;9:22
pubmed: 24524281
Appl Health Econ Health Policy. 2010;8(5):343-50
pubmed: 20804226
Orphanet J Rare Dis. 2011 Sep 27;6:62
pubmed: 21951518
Int J Technol Assess Health Care. 2007 Winter;23(1):36-42
pubmed: 17234015
PLoS One. 2015 Oct 09;10(10):e0140002
pubmed: 26451948
PLoS One. 2016 Oct 21;11(10):e0164681
pubmed: 27768685
Value Health. 2012 Dec;15(8):1185-91
pubmed: 23244823